Delivery Order SPE2DB20D3101-SPE2DB25FRNG1
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Valganciclovir 450 mg tablets in quantities of 60 units, with a ceiling value of $12,058.08. This non-set-aside, firm fixed-price delivery order is scheduled for completion by July 21, 2025, with fulfillment performed from AmerisourceBergen's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 60 count bottles of 450 mg valganciclovir tablets. This $2,050.03 award has an ultimate completion date of April 12, 2024 and does not have a set-aside designation. AmerisourceBergen Drug Corp, a for-profit organization, serves as the prime contractor and provides a wide range of pharmaceutical products and medical...
- The Defense Logistics Agency awarded a $11,387.15 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Valganciclovir 450 mg, an antiviral medication commonly used to treat cytomegalovirus infections in immunocompromised patients. This non-set-aside competitive award was issued on August 22, 2025, with an ultimate completion date of August 25, 2025, and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply contract vehicle. The...
- The Defense Logistics Agency awarded a delivery order valued at $3,832.16 to AmerisourceBergen Drug Corp for the supply of Valganciclovir 450 mg tablets (60-count units) under a firm fixed price contract type. The award was made on August 25, 2025, with an ultimate completion date of August 26, 2025, and represents a competitively awarded, non-set-aside contract. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Valganciclovir HCL 50 mg/ml in an 88ml unit, valued at $3,439.80 under firm fixed pricing. This delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026. The product will be delivered to...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Valganciclovir HCL 50 mg/ml (88 ml) on August 11, 2025, with a ceiling value of $1,024.62. This is a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and represents a non-competitive set-aside. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement,...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 60 units of the medication Valganciclovir 450 mg tablets, with a ceiling value of $2,585.74 and a completion date of July 7, 2025. The contract has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on September 19, 2025, for the supply of Valganciclovir 450 mg tablets in unit dose packages of 20 tablets. This is a firm fixed-price contract valued at $7,046.46, with an ultimate completion date of September 22, 2025. The contract carries no set-aside designation and represents a competitive award. AmerisourceBergen will perform this delivery from its corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Valganciclovir 450 mg tablets (60-count) under a firm fixed-price contract valued at $1,081.86. This is a non-set-aside competitive award with an ultimate completion date of September 19, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 450 mg valganciclovir tablets, a medication used to treat cytomegalovirus infections. The contract has a ceiling value of $5,341.60 and a period of performance through June 11, 2025. It is a firm-fixed-price contract with no set-aside designation, indicating open...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRNG1Delivery Order
The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Valganciclovir 450 mg tablets (60-count packages) under a firm fixed-price contract valued at $4,031.70. This non-set-aside award was issued on June 18, 2025, with an ultimate completion date of June 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Valganciclovir is an antiviral medication used to treat cytomegalovirus infections, representing the type of specialized pharmaceutical product that the Defense Logistics Agency procures to support military and veteran healthcare systems. This delivery order operates as a child contract under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor in the federal medical supply chain, supplying a comprehensive range of medications, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. The company's competitively awarded contracts with DLA demonstrate its established capability to fulfill federal pharmaceutical procurement requirements efficiently across a wide spectrum of product categories and order values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 6/18/25 |